CRSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRISPR Therapeutics is not a clear buy right now for a Beginner with a long-term horizon and $50,000-$100,000 to deploy. The stock has solid long-term potential and strong cash resources, but the current setup is mixed: the price trend is weak, the latest quarter missed EPS expectations, insider selling is rising, and there is no strong proprietary buy signal today. For an impatient investor who does not want to wait for a better entry, this is not the right moment to buy aggressively. The best direct call is hold.
CRSP is trading near 52.51, just above pivot support at 52.08 but still under near-term resistance at 54.64. The technical picture is bearish to neutral: MACD histogram is negative and expanding, RSI_6 is 47.2 showing no momentum edge, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. That means the stock is still in a weak trend, and the current rebound is not yet confirmed as a sustained uptrend. The short-term pattern data suggests possible upside over the next week, but the broader trend remains unfavorable for an immediate long-term entry.
["Citi raised its price target to $82 and kept a Buy rating on 2026-05-06.", "BofA kept a Buy rating and said Q1 updates were encouraging with few changes to the core thesis.", "Q1 revenue grew 68.55% year over year to $1.458 million.", "Cash and marketable securities were strong at $2.44 billion as of March 31, 2026.", "The company priced a $550 million convertible debt offering to support R&D and commercialization.", "Casgevy momentum and future pipeline updates remain key event-driven upside catalysts."]
["The stock fell 4.83% during regular trading, showing weak immediate price action.", "Q1 GAAP EPS missed expectations at -$1.28.", "Net income remained deeply negative at -$122.9 million.", "Insiders have been selling, with selling up 476.16% over the last month.", "Technical trend is bearish with MACD negative and moving averages aligned unfavorably.", "Morgan Stanley still rates the stock Underweight, showing Wall Street remains divided.", "No AI Stock Picker or SwingMax signal is present today."]
In Q1 2026, CRISPR Therapeutics posted revenue of $1.458 million, up 68.55% year over year, which is a strong top-line growth rate. However, profitability remains weak: net income was -$122.9 million and EPS was -$1.28, both worse than a year ago. Gross margin was 100%, but that is not enough to offset the lack of earnings power yet. The latest quarter was a growth improvement story, not a profits story.
Analyst sentiment is mixed but leaning constructive. Recent target changes were mostly raised or maintained by bullish firms: Citi, BofA, Piper Sandler, Chardan, JPMorgan, and Needham all kept Buy/Overweight-type views with targets mostly in the $76-$110 range. The bearish side is still present, with Morgan Stanley maintaining Underweight and TD Cowen holding at Hold with a $45 target. Wall Street pros see upside from pipeline progress, cash strength, and Casgevy momentum, but cons remain the lack of profitability, dependence on pipeline execution, and valuation uncertainty.
